GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US clinical stage caner drug developer Theriva Biologics revealed that the US Food and Drug Administration (FDA) has granted Rare Pediatric Drug designation (RPDD) for VCN-01 for the treatment of retinoblastoma. 1 August 2024
Eisai and Biogen have announced that Israel has approved their Alzheimer's treatment, Leqembi (lecanemab), adding to nods in the USA, Japan, China, South Korea, and Hong Kong. 12 July 2024
Contract research and development organization (CDMO) Emergent BioSolutions has announced that Johnson & Johnson will pay $50 million to resolve claims linked to a terminated manufacturing deal for the latter’s COVID-19 vaccine. 11 July 2024
Japan’s Eisai and US biotech Biogen have announced that the Department of Health in Hong Kong has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for treatment of Alzheimer’s disease (AD). 11 July 2024
PolTREG, a Polish biotech developing cell therapies for autoimmune diseases, has announced that its polyclonal Treg cell therapy PTG-007 demonstrated significant insulin secretion restoration in early-onset type-1 diabetes (T1D) patients, as well as a longer period of disease remission compared to a control group receiving standard-of-care. 24 June 2024
Indian drugmaker Cipla announced that its wholly-owned subsidiary in the UK, Cipla (EU) Limited, will invest an additional 3 million euros ($3.2 million) in Ethris GmbH, a German firm delivering mRNAs directly to the respiratory system. 19 June 2024
Dutch autoimmune diseases specialist Argenx announced that results from the Phase II ALPHA study of efgartigimod in post-COVID-19-mediated postural orthostatic tachycardia syndrome (PC-POTS) show that treated patients had no clinically meaningful improvement compared to placebo on the total Malmö POTS symptom (MaPS) score and COMPASS31. 17 June 2024
The US Food and Drug Administration (FDA) has accepted Eisai’s supplemental Biologics License Application (sBLA) for monthly Leqembi (lecanemab-irmb) intravenous (IV) maintenance dosing. 10 June 2024
The European Medicines Agency (EMA) has approved a Type II variation to the Summary of Product Characteristics (SmPC) for its approved Chimeric Antigen Receptor (CAR) T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) from Gilead Sciences’ Kite subsidiary. 6 June 2024
Ipsen shares began trading around 2% higher on Thursday morning, after the French biotech announced today it would restart the global Phase III MOVE trial, in people over the age of 14. 26 March 2020
Sino-America immuno-oncology biotech firm BeiGene today announced that, on March 25, 2020, the China National Medical Products Administration (NMPA) suspended the importation, sales and use of Abraxane (nanoparticle albumin-bound paclitaxel) in China supplied to BeiGene by Celgene, now a Bristol-Myers Squibb company. 25 March 2020
Danish CNS specialist Lundbeck has published positive data from the Phase III PROMISE 2 trial in Neurology, the medical journal of the American Academy of Neurology. 25 March 2020
US biotech Forge Therapeutics has entered into a research collaboration and option agreement with Swiss pharma giant Roche to license FG-LpxC LUNG, a novel antibiotic for the treatment of serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa. 25 March 2020
German biotechnology firm Sartorius has supported CanSino Biologics and Major General Chen Wei’s team at the Institute of Bioengineering at the Academy of Military Medical Sciences in China in their development of the first vaccine candidate against the novel coronavirus SARS-CoV-2 to enter clinical trials. 25 March 2020
Ono Pharmaceutical has received manufacturing and marketing approval for Velexbru (tirabrutinib) tablet 80mg, a Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of recurrent or refractory primary central nervous system lymphoma, in Japan. 25 March 2020
Netherlands-based Norgine says it has acquired Azanta, a Denmark-based specialty biopharmaceutical company operating within women’s healthcare, addiction medicine and oncology. Azanta becomes a wholly-owned subsidiary of Norgine. 25 March 2020
The Ghent, Belgium-based Flanders Interuniversity Institute for Biotechnology (VIB) is to conduct a trial, together with the University Hospital Ghent, to test Leukine (sargramostim) against respiratory illness caused by COVID-19. 25 March 2020
UK novel RNA therapeutics specialist Silence Therapeutics saw its sales rocket 32% to 535.00 pence as markets opened today, as it announced a strategic collaboration with AstraZeneca to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for cardiovascular, renal, metabolic and respiratory diseases. 25 March 2020
As the world watches aghast, the novel coronavirus continues to spread its tentacles around the globe, with cases of COVID-19 rising to nearly 375,000 on Tuesday, an increase of 75,000 from the day before. 25 March 2020
Austro-American company CEL-SCI Corporation and the University of Georgia’s (UGA) Center for Vaccines and Immunology have announced a collaboration in COVID-19. 24 March 2020
Stock in Novavax rose more than 15% by early afternoon on Tuesday, after the US vaccine developer announced positive data for a Phase III clinical trial of NanoFlu. 24 March 2020
Due to overwhelming demand, US biotech giant Gilead Sciences is temporarily stopping compassionate-use of its remdesivir, in order to focus supplies of the investigational antiviral for clinical testing as a possible treatment for the new coronavirus, COVID-19. 24 March 2020
Belgian mRNA company eTheRNA Immunotherapies has announced that a consortium has been formed with North American and European partners to develop a vaccine against SARS-CoV-2 and preclinical development has started. 24 March 2020
Ireland-headquartered Ovoca Bio saw its shares gain more than 7% to 7.50 pence, after it announced an agreement to acquire the remaining shareholding in Russian biotech firm IVIX that the company does not already control. 24 March 2020
Boston, USA-based biotech Pieris Pharmaceuticals has announced that its immuno-oncology collaboration with independent French drugmaker Servier is now to be focused on the two most advanced programs. 24 March 2020
Data published at a virtual Clinical Trial Session, conducted by the Muscular Dystrophy Association (MDA), show Zolgensma (onasemnogene abeparvovec-xioi) produced significant benefit to people with spinal muscular atrophy (SMA). 24 March 2020
South Korea's Celltrion Healthcare on Monday announced key milestones in its efforts to fight the 2019 novel coronavirus (COVID-19) pandemic. 24 March 2020